- Home
- Companies
- canada quebec
- biomarker development
Refine by
Biomarker Development Suppliers Serving Canada Quebec
47 companies found
Premium
based inFramingham, MASSACHUSETTS (USA)
SCIEX empowers you to solve the most impactful analytical challenges in quantitation and characterization in environmental testing. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field ...
based inPalo Alto, CALIFORNIA (USA)
Nirmidas Biotech was founded in September of 2013. We are a member of the Janssen Labs (JLABS) and QB3 programs, the Stanford StartX Med Program, and the MIT Industrial Liaison Program (MIT ILP). We are also a StartX Med COVID-19 Task Force Company ...
based inHayward, CALIFORNIA (USA)
Novodiax is dedicated to advancing tissue-based diagnostics and immunoassays through innovation. Our signature technology platform is a proprietary polymer-based detection system. Based on this technology we have developed a series of highly ...
Use the Novodiax polymerized horseradish peroxidase (polyHRP) signal amplification technology (ihcDirect) and conjugate it directly to your humanized antibody-of-choice to enable rapid, sensitive IHC testing. Jumpstart your early humanized ...
based inHuningue, FRANCE
FIRALIS is a biotechnology company located in the very heart of BioValley, on the true triple border of FR-DE-CH, only a few minutes walking distance to Basel, the pharmaceutical capital of Europe. Firalis creates novel values via biomarker ...
NEUROLINCS : A non-invasive in-vitro diagnostic test measuring 7494 brain-enriched long non-coding RNAs (lncRNAs) that are specific to neurodegenerative ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Predicting immunotherapy outcome with AI analysis; Finding more responders to cancer treatment; Tissue Data is huge and complex; Complex is what AI does ...
based inSeongnam-si, SOUTH KOREA
Theramx Inc. was founded on the conviction that health, and the extension of life, is one of the important values that can be provided to humankind. Our company develops treatment platforms that provide the best diagnoses and treatments. As a ...
Technology that excavates biomarkers through an analysis of brainwaves in epilepsy or Alzheimer’s patients, predicts the likelihood of onset, or diagnoses the advance, based on the degree of change of brainwave biomarkers measured by a ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
The outcome of your research is directly linked to the quality of the used biospecimen. In order to reflect the molecular reality, the biospecimen quality benefits from our standardized sampling by Indivumed study nurses and Indivumed trained ...
based inRockville, MARYLAND (USA)
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine ...
based inSan Francisco, CALIFORNIA (USA)
Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our ...
based inParis, FRANCE
Ariana Pharma is a leading Al driven Precision Medicine Company focused on accelerating clinical drug development and designing advanced therapeutic decision support systems. Using its KEM Explainable Artificial Intelligence (XAl) technology, Ariana ...
Ariana Pharma has developed KEM® (Knowledge Extraction and Management) the most advanced Explainable Artificial Intelligence platform based on Galois Lattices (also known as Formal Concept Analysis or FCA). KEM® uses association rules to ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
Gencurix R&D Center is performing ceaseless research activities to developing the ‘multiplex assay’ which is core technology for economy in expenditures, time and samples. We have accumulated research capabilities and experiences of ...
based inOklahoma City, OKLAHOMA (USA)
By launching first-in-market biomarker tests and developing digital biomarkers for the continuous monitoring of disease, we support clinicians in their effort to provide exceptional care. Our technologies will empower clinician decision making and ...
based inBangalore, INDIA
Cellworks’ mission is to serve patients through advances in personalized medicine that significantly improve treatment success. We achieve better outcomes by predicting a successful match between patients and drug therapies – their Therapy Response ...
Accelerate drug development timelines, reduce risks and lower costs. Our biosimulation platform predicts human clinical response to investigational drug candidates YEARS earlier than traditional development ...
based inVienna, AUSTRIA
We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Unlocking the potential of precision medicine with Artificial Intelligence – enabled data-driven insights. Advance targeted therapy development by harnessing the power of data and multimodal analytics. Advances in molecular ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Identify the biomarkers best suited for your needs: Diagnose rare or ambiguous diseases, Group patients by endotype response for prognosis, Assess disease etiology to determine responsive patient group ...
based inSeattle, WASHINGTON (USA)
Headquartered in Seattle, Avaden Biosciences operates the largest human biosample network in the world. Our U.S.-based partnerships with over 200 CLIA/CAP accredited facilities provide immediate access to more than 35,000,000 highly annotated ...
based inBrea, CALIFORNIA (USA)
We are pleased to announce the exclusive commercialization and sale of KinesisDx product lines to Krishgen Biosystems, India for worldwide usage effective July 11, 2019. This is in line with our philosophy to partner with forward looking companies ...
based inVienna, AUSTRIA
Biomedica is part of the AddLife Group, a publicly traded parent company consisting of various subsidiaries in the Life Science and Medical Device fields. AddLife strives to improve people’s lives by being a leading, value creating player in Life ...
We offer custom testing service measurements for the quantification of biomarkers in biological samples. Our experienced laboratory staff perform all sample service measurements, allowing customers to fully rely on the data without having to invest ...
based inUppsala, SWEDEN
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help ...
Casting a broader net to further explore the complexity of the human proteome. Complementing and expanding on our previous portfolio of disease area-focused biomarker panels, our exploratory panels offers scientists the chance to cast a wider net in ...
